Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness

Hiromichi Ito, James Gardner-Thorpe, Michael J. Zinner, Stanley W. Ashley, Edward E. Whang

Research output: Contribution to journalArticle

Abstract

Background. Src is a 60-kDa tyrosine kinase that plays a critical role in signal transduction associated with cell-extracellular matrix interactions. We tested the hypothesis that Src inhibition might suppress pancreatic cancer cellular invasiveness. Methods. We tested the effects of pyrazolopyrimidine (a Src kinase-specific inhibitor) on 3 human pancreatic cancer cell lines: BXPC-3, MIAPaCa-2, and PANC-1. Src expression was assayed with Western blotting. Pyrazolopyrimidine-mediated inhibition of Src phosphorylation was confirmed by immunoprecipitation. Matrix metalloproteinase (MMP) activities and cellular invasive potential were assessed by use of zymography and Boyden chamber assays, respectively. Cell growth was assessed with the MTT assay. Results. Src was expressed in all 3 pancreatic cancer cell lines tested. Pyrazolopyrimidine completely suppressed Src phosphorylation, inhibited MMP2 (72kDa) and MMP9 (92kDa) activities by 40% to 34% (P <.05), and suppressed cellular invasiveness by more than 90% (P <.05) in all 3 cell lines. Pyrazolopyrimidine had variable effects on cell growth: 50% reduction (P <.05) in BXPC-3, 7% reduction (P > .05) in MIAPaCa-2, and 22% reduction (P <.05) in PANC-1. Conclusion. Inhibition of Src signaling results in a marked reduction of pancreatic cancer cellular invasiveness. Src may represent a novel therapeutic target for this deadly cancer.

Original languageEnglish (US)
Pages (from-to)221-226
Number of pages6
JournalSurgery
Volume134
Issue number2
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

src-Family Kinases
Pancreatic Neoplasms
Phosphorylation
Cell Line
Matrix Metalloproteinases
Immunoprecipitation
Protein-Tyrosine Kinases
Extracellular Matrix
Signal Transduction
Western Blotting
Growth
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Ito, H., Gardner-Thorpe, J., Zinner, M. J., Ashley, S. W., & Whang, E. E. (2003). Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery, 134(2), 221-226. https://doi.org/10.1067/msy.2003.224

Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. / Ito, Hiromichi; Gardner-Thorpe, James; Zinner, Michael J.; Ashley, Stanley W.; Whang, Edward E.

In: Surgery, Vol. 134, No. 2, 01.08.2003, p. 221-226.

Research output: Contribution to journalArticle

Ito, H, Gardner-Thorpe, J, Zinner, MJ, Ashley, SW & Whang, EE 2003, 'Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness', Surgery, vol. 134, no. 2, pp. 221-226. https://doi.org/10.1067/msy.2003.224
Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery. 2003 Aug 1;134(2):221-226. https://doi.org/10.1067/msy.2003.224
Ito, Hiromichi ; Gardner-Thorpe, James ; Zinner, Michael J. ; Ashley, Stanley W. ; Whang, Edward E. / Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. In: Surgery. 2003 ; Vol. 134, No. 2. pp. 221-226.
@article{a3b19d9b070b4b0f989ee6e126e9063a,
title = "Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness",
abstract = "Background. Src is a 60-kDa tyrosine kinase that plays a critical role in signal transduction associated with cell-extracellular matrix interactions. We tested the hypothesis that Src inhibition might suppress pancreatic cancer cellular invasiveness. Methods. We tested the effects of pyrazolopyrimidine (a Src kinase-specific inhibitor) on 3 human pancreatic cancer cell lines: BXPC-3, MIAPaCa-2, and PANC-1. Src expression was assayed with Western blotting. Pyrazolopyrimidine-mediated inhibition of Src phosphorylation was confirmed by immunoprecipitation. Matrix metalloproteinase (MMP) activities and cellular invasive potential were assessed by use of zymography and Boyden chamber assays, respectively. Cell growth was assessed with the MTT assay. Results. Src was expressed in all 3 pancreatic cancer cell lines tested. Pyrazolopyrimidine completely suppressed Src phosphorylation, inhibited MMP2 (72kDa) and MMP9 (92kDa) activities by 40{\%} to 34{\%} (P <.05), and suppressed cellular invasiveness by more than 90{\%} (P <.05) in all 3 cell lines. Pyrazolopyrimidine had variable effects on cell growth: 50{\%} reduction (P <.05) in BXPC-3, 7{\%} reduction (P > .05) in MIAPaCa-2, and 22{\%} reduction (P <.05) in PANC-1. Conclusion. Inhibition of Src signaling results in a marked reduction of pancreatic cancer cellular invasiveness. Src may represent a novel therapeutic target for this deadly cancer.",
author = "Hiromichi Ito and James Gardner-Thorpe and Zinner, {Michael J.} and Ashley, {Stanley W.} and Whang, {Edward E.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1067/msy.2003.224",
language = "English (US)",
volume = "134",
pages = "221--226",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness

AU - Ito, Hiromichi

AU - Gardner-Thorpe, James

AU - Zinner, Michael J.

AU - Ashley, Stanley W.

AU - Whang, Edward E.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background. Src is a 60-kDa tyrosine kinase that plays a critical role in signal transduction associated with cell-extracellular matrix interactions. We tested the hypothesis that Src inhibition might suppress pancreatic cancer cellular invasiveness. Methods. We tested the effects of pyrazolopyrimidine (a Src kinase-specific inhibitor) on 3 human pancreatic cancer cell lines: BXPC-3, MIAPaCa-2, and PANC-1. Src expression was assayed with Western blotting. Pyrazolopyrimidine-mediated inhibition of Src phosphorylation was confirmed by immunoprecipitation. Matrix metalloproteinase (MMP) activities and cellular invasive potential were assessed by use of zymography and Boyden chamber assays, respectively. Cell growth was assessed with the MTT assay. Results. Src was expressed in all 3 pancreatic cancer cell lines tested. Pyrazolopyrimidine completely suppressed Src phosphorylation, inhibited MMP2 (72kDa) and MMP9 (92kDa) activities by 40% to 34% (P <.05), and suppressed cellular invasiveness by more than 90% (P <.05) in all 3 cell lines. Pyrazolopyrimidine had variable effects on cell growth: 50% reduction (P <.05) in BXPC-3, 7% reduction (P > .05) in MIAPaCa-2, and 22% reduction (P <.05) in PANC-1. Conclusion. Inhibition of Src signaling results in a marked reduction of pancreatic cancer cellular invasiveness. Src may represent a novel therapeutic target for this deadly cancer.

AB - Background. Src is a 60-kDa tyrosine kinase that plays a critical role in signal transduction associated with cell-extracellular matrix interactions. We tested the hypothesis that Src inhibition might suppress pancreatic cancer cellular invasiveness. Methods. We tested the effects of pyrazolopyrimidine (a Src kinase-specific inhibitor) on 3 human pancreatic cancer cell lines: BXPC-3, MIAPaCa-2, and PANC-1. Src expression was assayed with Western blotting. Pyrazolopyrimidine-mediated inhibition of Src phosphorylation was confirmed by immunoprecipitation. Matrix metalloproteinase (MMP) activities and cellular invasive potential were assessed by use of zymography and Boyden chamber assays, respectively. Cell growth was assessed with the MTT assay. Results. Src was expressed in all 3 pancreatic cancer cell lines tested. Pyrazolopyrimidine completely suppressed Src phosphorylation, inhibited MMP2 (72kDa) and MMP9 (92kDa) activities by 40% to 34% (P <.05), and suppressed cellular invasiveness by more than 90% (P <.05) in all 3 cell lines. Pyrazolopyrimidine had variable effects on cell growth: 50% reduction (P <.05) in BXPC-3, 7% reduction (P > .05) in MIAPaCa-2, and 22% reduction (P <.05) in PANC-1. Conclusion. Inhibition of Src signaling results in a marked reduction of pancreatic cancer cellular invasiveness. Src may represent a novel therapeutic target for this deadly cancer.

UR - http://www.scopus.com/inward/record.url?scp=0042829207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042829207&partnerID=8YFLogxK

U2 - 10.1067/msy.2003.224

DO - 10.1067/msy.2003.224

M3 - Article

C2 - 12947321

AN - SCOPUS:0042829207

VL - 134

SP - 221

EP - 226

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -